Abstract: antiperspirant compositions comprise an antiperspirant active and a carrier oil in which the carrier oil comprises an aromatic ester oil obeying the general formula: R1—CO2—X—Y—R2 in which R1 and R2 each represent a phenyl group, X represents an alkylene group containing from 2 to 4 carbons including at least one pendant alkyl group and Y represents a bond, or an ether or ester linkage.

Abstract: Disclosed are surfactant compounds and compositions that are antimicrobial. Also provided are polymeric compositions incorporating the surfactant compounds. The polymeric compositions may be used to form antibacterial coatings on surfaces.

Abstract: An object of the present invention is to provide a therapeutic agent for diabetes mellitus or insulin resistance improving agent, or to provide foods and drinks, food and drink additives, and feeds or feed additives for treating diabetes mellitus or improving insulin diabetes. In order to achieve such an object, the present invention provides a therapeutic agent for diabetes mellitus and insulin resistance improving agent comprising hydroxyproline, a hydroxyproline derivative or a pharmaceutically acceptable salt thereof or foods and drinks, food and drink additives, feeds or feed additives for treatment of diabetes mellitus or improvement of insulin resistance comprising the same.

Abstract: The invention relates to a process for dissolving at least one compound of low solubility in water, the said process comprising the essential step of mixing the compound of low solubility with at least one lipophilic amino acid derivative. The invention also relates to a cosmetic or dermatological composition comprising, in a physiologically acceptable medium, at least one compound of low solubility and at least one lipophilic amino acid derivative. Among the compounds of low solubility that are especially included are aminophenol derivatives, salicylic acid derivatives, 2-amino-4-alkylaminopyrimidine 3-oxide derivatives and DHEA, and also its chemical or metabolic derivatives and precursors.

Abstract: The invention disclosed in this document is related to field of pesticides and their use in controlling pests. In particular compounds having the following formula are disclosed.

Abstract: A transdermal patch suitable for the administration of nitroglycerin.

Abstract: The present invention provides, in one aspect, a physiological cooling composition comprising at least one cyclohexane carboxamide, at least one acyclic carboxamide, and at least one stereoisomer of menthyl lactate. In another aspect, disclosed is a method for producing such composition. In still another aspect, disclosed are various consumer products comprising a physiological cooling composition comprising at least one cyclohexane carboxamide, at least one acyclic carboxamide, and at least one stereoisomer of menthyl lactate.

Abstract: A heat-generating composition comprises a substituted polyhydric alcohol and a fatty acid ester, the composition having the structure of: wherein R? is H, CH3—(O[CH2]n)z—OH, or and wherein x+y, x+y+z or w+x+y+z, or combinations thereof, has an average value ranging from about 6 to about 100; wherein R is a hydrocarbon or mixture of alkyl groups comprising from about 3 to about 19 carbons, wherein n is an integer ranging from about 2 to about 4, or combinations thereof; and m is an integer ranging from about 0 to about 6. Interaction of the composition with an aqueous composition generates heat, characterized by a temperature increase from about 5 degrees C. to about 15 degrees C. Products containing the heat-generating composition can be applied to a surface in a two-step process, the first step being application of the composition, followed by the aqueous composition. The heat-generating composition can be used in cosmetics and personal care products.

Abstract: 3,5-di-substituted-4-hydroxybenzylidene phosphonates and sulfonates useful in treating inflammatory disease, particularly osteoarthritis, and elastomeric particles for oral delivery of drugs are disclosed.

Abstract: Disclosed herein are compound useful for inhibition of hormone sensitive lipase, pharmaceutical compositions of these compounds, and methods of treatment using these compounds.

Abstract: The invention is concerned with novel hexafluoroisopropanol substituted ether derivatives of formula (I): wherein R1 to R3 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Abstract: A method and apparatus are disclosed for treating asthma and other respiratory conditions. A medicament comprising a surface active phospholipid (SAPL) is prepared in the form of a fine powder and administered to the lungs in a gas stream. A preferred SAPL is a solid blend of diplamitoyl choline and phosphatdiyl glycerol (PG).

Abstract: Methods of treating and/or preventing otitis media in a subject are provided. Methods of treating and/or preventing otitis externa are also provided.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A system, method and apparatus provices an antimicrobial card, badge holder or token made from an antimicrobial polymereric material. The antimicrobial polymereric material includes one or more polymers and one or more antimicrobial agents that affect the growth of bacteria, fungi, virus or a combination thereof.

Abstract: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.

Abstract: Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear a-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 ?m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung.

Abstract: The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.

Abstract: Pharmaceutical proton pump inhibitor (PPI) medications and methods are disclosed for preventing and/or treating gastrointestinal disorders characterized by abnormalities in gastric acid secretion at anytime of the day or night without the need for food effect or to be taken with food. The medications comprise a PPI and a cholinergic agonist for inducing rapid onset of PPI action, for increasing the duration of PPI efficacy and for optimizing clinical PPI effectiveness that may be administered at any time of the day or night without food or on an empty stomach, and possibly on an as-needed or on demand basis. In carrying out the methods, a PPI and cholinergic agonist may be administered together as a single unitary dose in the form of a liquid or solid, or administered together, but separately as either liquids or solids or a combination thereof. Preferably, an oral solid dosage form of the present invention allows for release of a proton pump inhibitor at a pH of about 5 or higher, e.g., pH about 5.5, 6, 6.

Abstract: The present invention relates to a composition comprising a) an anionic compound having wetting and dispersing properties selected from the group of a1) an alkyl naphthalene sulfonate, a2) a naphthalene sulfonate-formaldehyde condensate that may optionally be alkyl substituted and mixtures thereof, and b) a nitrogen-containing surfactant selected from the group consisting of alkylamine alkoxylates, alkylamidoamine alkoxylates, alkanolamides and their alkoxylates, alkylamidopropylamines, betaines, amino acids, or any mixtures thereof, wherein <the weight ratio between a) and b) is between 99.99:0.01 and 40:60 while> the molar amount of anionic sulfonate and, if any are present, carboxylate groups in the composition is in excess of the molar amount of nitrogen-containing groups. These compositions exhibit synergistic wetting properties as compared to the surface-active components taken alone. Further, the compositions also exhibit an increased rainfastness.

Abstract: Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered lactic acid, tris(tetramethylhydroxypiperidinol) citrate, a boswellic acid compound, and salts, isomers, derivatives, and mixtures of any of the foregoing; and a dermatologically acceptable carrier.

Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally.

Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

Abstract: The use is described of merocyanine derivatives of formula (1), wherein R1 and R2 are each independently of the other hydrogen; C1-C22alkyl; cyclo-C3C8alkyl; or unsubstituted or C1-C5alkyl- or C1-C5alkoxy-substituted C6-C20aryl; orl; or R1 and R2 together with the nitrogen atom linking them form a —(CH2)m— ring which is uninterrupted or, interrupted by —O— or by —NH—; R3 is a cyano group; —COOR5; —CONHR5; —COR5; or —SO2R5; R4 is a cyano group; —COOR6; —CONHR6; —COR6; or —SO2R6; R5 and R6 are each independently of the other C1-C22alkyl; or unsubstituted or C1-C5alkyl substituted C6-C20aryl; or R3 and R4 together or R5 and R6 together form in a 5- to 7-membered, monocyclic, carbocyclic or heterocyclic ring; Z1, and Z2 are each independently of the other a —(CH2)n— group which is uninterrupted or interrupted by —O—, —S—, or by —NR7—, and/or is unsubstituted or substituted by C1-C5alkyl; R7 is (ClC5alkyl; 1 is from 1 to 4; m is from 1 to 7; n is from 1 to 4; when n=2, R1, R5 or R6 is a bivalent alkyl group; or R1

Abstract: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Abstract: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.

Abstract: Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels and other disorder exacerbated by obesity.

Abstract: Methods, systems, and devices for medical therapy compliance for the treatment of onychomycosis with a topically applied antifungal agent.

Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic or locally acting non-steroidal anti-inflammatory drug to an animal which comprises applying an effective amount of the non-steroidal anti-inflammatory drug in the form of the drug delivery system of the present invention.

Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally.

Abstract: A pharmaceutical composition comprises a pharmaceutically effective amount of an active ingredient and low crystallinity cellulose having a crystallinity index of less than about 75% as measured by X-ray diffraction. The compositions advantageously may be provided in tablet form or granulate form and provide good stability against moisture degradation.

Abstract: The invention relates to methods of treatment and pharmaceutical compositions of new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isoomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.

Abstract: Angiogenesis, tumor growth, and metalloproteinase 2 (MMP2) interaction with integrin-?v?3 are inhibited by an inhibitor compound of formula: wherein G1 and G2 are each independently —NH—C(O)—O—(CH2)v—(C6H4)—X3 ; Y1 and Y2 are each independently —OH or C1-C4 alkoxy; X1 and X2 are each independently halo or C1-C4 alkoxy; X3 is fluoro, nitro, C1-C4 alkyl, C1-C4 alkoxy, or C1-C4 perfluoroalkyl; Z is —C?C—, —C6H4—, cis-CH?CH—, trans-CH?CH—, cis-CH2—CH?CH—CH2—, trans-CH2—CH?CH—CH2—, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each 1; t is an integer having a value of 0 or 1; p and r are each 2, and v is 1; with the proviso that when A is H, t is 0, and when A is a covalent bond, t is 1.

Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

Abstract: Substituted phenol derivatives of Formula (I) are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

Abstract: The present invention is directed toward substituted hydroxyethylene compounds of formula (XII) useful in treating Alzheimer's disease and other similar diseases.

Abstract: Novel compositions and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a substance having serine protease inhibitory activity or serpin activity. Among the substances found to be useful are ?1-antitrypsin (AAT), peptide derivatives from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviridae family.

Abstract: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, personal care, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Abstract: The present invention concerns screening methods and compositions relating to endothelial cell function. More specifically, it provides screening methods to identify or characterize pathways and factors involved in endothelial cell function by employing conditions that simulate physiological stress. Additional methods can be implemented to identify candidate drugs for the treatment of endothelial cell dysfunction, such as cardiovascular disease or diabetes.

Abstract: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids.

Abstract: The present invention is a composition comprising a neonicotinoid-based compound having a high degree of insecticide activity, an organic solvent and a surfactant. The present invention is also a method that allows the obtaining of lumber that does not require termite-proofing treatment following production of lumber by injecting this composition into a tree trunk and allowing the chemical to circulate and disperse within the tree trunk.

Abstract: The invention concerns the use in a cosmetic composition of at least a poly-aminoacid of general formula (I) in which X is —O—, —S— or —NR3; R1 represents in particular a hydrogen atom or a C1-C40 alkyl radical; R2 represents in particular a hydrogen atom or an optionally substituted alkyl radical; R3 represents a hydrogen atom or an alkyl radical; R4 represents a hydrogen atom or a radical such as NH2, OH, SH, —CHOHCH3, —CONH2; n is a number greater than 1 such that the poly-aminoacid derivative molecular weight ranges between 200 and 200000.

Abstract: Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.

Abstract: The invention provides the combined use of an inhibitor of formation or release of ?-amyloid and a nitric oxide releaser for the treatment or prevention of Alzheimer's disease.

Abstract: This invention is directed to compounds of the following formula (I): wherein R is either: wherein R1 and R2 are as defined in the specification; the use of these compounds for treating inflammatory disorders; and pharmaceutical compositions comprising a therapeutically effective amount of the above-defined compounds.

Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.

Abstract: The present invention is directed to a water-in-oil emulsion composition comprising: a lipophilic personal care composition comprising by weight: (a) from about 1% to about 30% of a polyglycerin fatty acid ester having a polyglycerin of 2-20 units and at least one branched fatty acid residue of 8 to 22 carbons; (b) from about 0.01% to about 6% of glycerin, wherein the amount of glycerin is no more than 20% of the polyglycerin fatty acid ester; (c) from about 0.001% to no more than an amount dissolvable in glycerin of a water-soluble skin benefit agent; and (d) a lipophilic carrier which is substantially free of surfactant.